17,176 Shares in RadNet, Inc. $RDNT Acquired by Formula Growth Ltd.

Posted by Brian Himes on Aug 28th, 2026

Formula Growth Ltd. bought a new stake in shares of RadNet, Inc. (NASDAQ:RDNT – Free Report) in the 2nd quarter, HoldingsChannel reports. The firm bought 17,176 shares of the medical research company’s stock, valued at approximately $1,059,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Corient Private Wealth LP purchased a new stake in shares of RadNet during the 2nd quarter valued at $223,000. Punch & Associates Investment Management Inc. purchased a new position in RadNet in the second quarter worth $39,054,000. Bamco Inc. NY purchased a new position in RadNet in the second quarter worth $77,765,000. Bank of America Corp DE bought a new position in RadNet in the second quarter valued at $25,942,000. Finally, Odyssean LLC increased its stake in RadNet by 377.9% in the second quarter. Odyssean LLC now owns 52,421 shares of the medical research company’s stock valued at $3,233,000 after acquiring an additional 41,452 shares during the last quarter. Hedge funds and other institutional investors own 77.90% of the company’s stock.

RadNet Price Performance

RDNT stock opened at $75.36 on Friday. The firm has a market cap of $5.93 billion, a P/E ratio of -279.10 and a beta of 1.36. The firm’s fifty day moving average is $66.89 and its 200 day moving average is $62.20. RadNet, Inc. has a 52 week low of $50.82 and a 52 week high of $85.84. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.48.

RadNet (NASDAQ:RDNT – Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The medical research company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.09. RadNet had a negative net margin of 0.93% and a positive return on equity of 2.61%. The business had revenue of $622.72 million during the quarter, compared to the consensus estimate of $610.87 million. During the same period in the previous year, the firm posted $0.31 earnings per share. The firm’s revenue for the quarter was up 25.0% on a year-over-year basis. Research analysts predict that RadNet, Inc. will post 0.49 earnings per share for the current year.

Insider Activity

In other news, Director David L. Swartz sold 2,699 shares of the business’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $53.89, for a total value of $145,449.11. Following the completion of the sale, the director owned 177,013 shares of the company’s stock, valued at approximately $9,539,230.57. The trade was a 1.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Cornelis Wesdorp sold 4,750 shares of the business’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $58.11, for a total value of $276,022.50. Following the completion of the sale, the chief executive officer directly owned 69,075 shares of the company’s stock, valued at approximately $4,013,948.25. This trade represents a 6.43% decrease in their position. The disclosure for this sale is available in the SEC filing. 5.14% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on RDNT shares. Zacks Research upgraded RadNet from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. Jefferies Financial Group reiterated a “buy” rating on shares of RadNet in a report on Friday, July 31st. Truist Financial increased their price objective on RadNet from $90.00 to $94.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Barclays decreased their price objective on RadNet from $70.00 to $65.00 and set an “overweight” rating on the stock in a report on Wednesday, May 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of RadNet in a research report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, RadNet has an average rating of “Moderate Buy” and a consensus price target of $88.00.

Check Out Our Latest Report on RDNT

RadNet Profile

(Free Report)

RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.

Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.